Akari Therapeutics Plc (AKTX): Price and Financial Metrics


Akari Therapeutics Plc (AKTX): $0.54

0.01 (+1.64%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add AKTX to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

AKTX Stock Price Chart Interactive Chart >

Price chart for AKTX

AKTX Price/Volume Stats

Current price $0.54 52-week high $1.66
Prev. close $0.53 52-week low $0.38
Day low $0.50 Volume 49,700
Day high $0.55 Avg. volume 79,058
50-day MA $0.54 Dividend yield N/A
200-day MA $0.97 Market Cap 40.11M

Akari Therapeutics Plc (AKTX) Company Bio


Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapeutics to treat rare and orphan autoimmune and inflammatory diseases. The company is based in London, United Kingdom.


AKTX Latest News Stream


Event/Time News Detail
Loading, please wait...

AKTX Latest Social Stream


Loading social stream, please wait...

View Full AKTX Social Stream

Latest AKTX News From Around the Web

Below are the latest news stories about AKARI THERAPEUTICS PLC that investors may wish to consider to help them evaluate AKTX as an investment opportunity.

Akari Therapeutics to Participate in the Ophthalmology Day at BTIG

NEW YORK and LONDON, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced that the company will participate in the Ophthalmology Day at BTIG on November 29, 2022. President and CEO Rachelle Jacques will participate in a fireside chat scheduled for 9:30 am ET.

GlobeNewswire | November 22, 2022

Akari Therapeutics Plc: Akari Therapeutics to Participate in the Ophthalmology Day at BTIG

NEW YORK and LONDON, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory disea…

Finanz Nachrichten | November 22, 2022

Short Volatility Alert: AKARI THERAPEUTICS

On Tuesday, shares of AKARI THERAPEUTICS (NASDAQ: AKTX ) experienced volatile short activity. After the activity, the stock price went down -6.39% to $0.571. The overall sentiment for AKTX has been Bearish. The signal from the volatility alert is trending Bearish. Therefore, the recommendation is to Increase Short Exposure. The volatility alert was produced on the prior trading date, 11/15/2022 with a volatility change of +67.08%. The current volatility indicator stands at 8.997. Overview: The securities lending volatility indicator is produced by Tidal Markets, in partnership with Benzinga Insights. Securities lending primarily serves … Full story available on Benzinga.com

Benzinga | November 16, 2022

Akari Therapeutics Plc: Akari Therapeutics Granted FDA Rare Pediatric Disease Designation of Nomacopan for the Treatment of Pediatric HSCT-TMA

NEW YORK and LONDON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory disea…

Finanz Nachrichten | November 10, 2022

Akari Therapeutics Granted FDA Rare Pediatric Disease Designation of Nomacopan for the Treatment of Pediatric HSCT-TMA

NEW YORK and LONDON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced the U.S. Food and Drug Administration (FDA) has granted the Rare Pediatric Disease Designation to nomacopan for the treatment of pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA). The Rare Pediatric Disease Designation is an important additi

Yahoo | November 10, 2022

Read More 'AKTX' Stories Here

AKTX Price Returns

1-mo 10.20%
3-mo -52.42%
6-mo -52.35%
1-year -66.04%
3-year -72.45%
5-year -88.84%
YTD -64.00%
2021 -18.92%
2020 5.71%
2019 11.46%
2018 -63.74%
2017 -38.49%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8223 seconds.